Recent News

• 02.27.2025 - uniQure Announces 2024 Financial Results and Highlights Recent Company Progress
• 02.03.2025 - uniQure Announces Completion of Enrollment in the First Cohort and Favorable Recommendation from the Independent Data Monitoring Committee for its Phase I/IIa Clinical Trial of AMT-191 for the Treatment of Fabry Disease
• 01.30.2025 - uniQure Announces Favorable Recommendation from Independent Data Monitoring Committee for its Phase I/II EPISOD1 Clinical Trial of AMT-162 for the Treatment of SOD1-ALS
• 01.30.2025 - uniQure Announces Favorable Recommendation from Independent Data Monitoring Committee for its Phase I/II EPISOD1 Clinical Trial of AMT-162 for the Treatment of SOD1-ALS
• 01.08.2025 - uniQure Announces Pricing of its Public Offering
• 01.07.2025 - uniQure Announces Proposed Public Offering
• 01.07.2025 - uniQure Announces Proposed Public Offering

Recent Filings

• 02.27.2025 - 4 Statement of changes in beneficial ownership of securities
• 02.27.2025 - 10-K Annual report [Section 13 and 15(d), not S-K Item 405]
• 02.27.2025 - 4 Statement of changes in beneficial ownership of securities
• 02.27.2025 - 8-K Current report
• 02.27.2025 - EX-99.1 EX-99.1
• 02.14.2025 - SCHEDULE 13G/A Statement of Beneficial Ownership by Certain Investors
• 01.08.2025 - 8-K Current report
• 01.08.2025 - EX-99.1 EX-99.1
• 01.08.2025 - 424B5 Prospectus [Rule 424(b)(5)]
• 01.07.2025 - 424B5 Prospectus [Rule 424(b)(5)]